Digital Health company Antidote Appoints Dr. Laurent Schockmel as new CEO. Founder Pablo Graiver to
Antidote Technologies, the digital health company that connects patients with medical research, today announced that Dr. Laurent Schockmel has been appointed as Chief Executive Officer. He will assume day-to-day leadership of the company and will also join Antidote’s Board of Directors. Founder and former CEO, Pablo Graiver, will continue to support the company as President.
“I started Antidote to help patients access new treatments which could lead to new cures for all of us and for future generations,” said Graiver, “and I’m very proud of the difference our mission-driven team has made in patients’ lives to date.
We’re now starting an exciting new stage in Antidote’s growth, and Laurent, with his rich background in life sciences, proven operational experience, and shared passion for our vision, is exactly what we needed to propel the business forward.”
Dr. Schockmel is a 30-year veteran of the life sciences, technology, data and services industries. With deep experience in clinical and commercial settings in the U.S. and Europe, he has served in leadership roles at organizations such as Truveris, IMS Health, Cegedim and Gemini Consulting. Dr. Schockmel has a track record of achieving dramatic advancements in customer innovation, quality, efficiency and overall company performance.
“I am thrilled to assume this role at Antidote,” said Schockmel. “I look forward to working closely with Antidote’s Board and talented team to continue innovating and delivering significant value to our customers, partners, employees, and shareholders.”
Antidote is a digital health company on a mission to accelerate the breakthroughs of new treatments by bridging the gap between medical research and the people who need it. In a world where 80% of clinical trials are delayed or closed due to lack of participants, Antidote uses cutting-edge technology to match the right patients with the right trials, helping medical researchers make faster progress, and offering new treatment options to patients.
Antidote Match™, the company's unique trial matching tool, currently powers clinical trial search for more than 250 patient communities and health portals — bringing clinical trial awareness, matching, and access to more than 15 million patients a month. Antidote was launched as TrialReach and is based in the US and UK. For more information, please visit www.antidote.me.